Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EyePoint Appoints Michael Campbell as Chief Commercial Officer
07:00am, Wednesday, 18'th Feb 2026
– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversig
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Tuesday, 17'th Feb 2026
WATERTOWN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
09:40am, Monday, 16'th Feb 2026
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
07:00am, Thursday, 05'th Feb 2026
WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Friday, 16'th Jan 2026
WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:26pm, Tuesday, 13'th Jan 2026
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
07:00am, Wednesday, 07'th Jan 2026
– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know
01:01pm, Monday, 22'nd Dec 2025
Does EyePoint (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
09:11am, Monday, 22'nd Dec 2025
EyePoint, ANI Pharmaceuticals and Tango Therapeutics put up a stellar show in 2025 and are set to carry the momentum in 2026 as well.
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 17'th Dec 2025
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Tuesday, 16'th Dec 2025
WATERTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – –
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 17'th Nov 2025
WATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript
02:31pm, Wednesday, 05'th Nov 2025
EyePoint Pharmaceuticals, Inc. ( EYPT ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants George Elston - Executive VP & CFO Jay Duker - President, CEO & Director Ramiro Ribeiro
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
09:16am, Wednesday, 05'th Nov 2025
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.54 per share a year ago.
